| poly ADP-ribose polymerase (PARP) inhibitor |
| olaparib | talazoparib |
mBC-Triple negative (TNBC) - 2nd Line (L2) 3 | | |
mBC - TNBC - L2 - all population 2 | | |
mBC - TNBC - L2 - PDL1 positive 2 | | |
Comparator:
vs Standard of Care (SoC);
Risk of bias:
low;
some concerns;
high;
NA;